Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Prostate Cancer Treatment (PDQ®) - PDQ Cancer Information

Androgen-targeted therapy in men with prostate cancer: evolving

Current Oncology, Free Full-Text

Abiraterone plus prednisone added to androgen deprivation therapy

Cancers, Free Full-Text

New Prostate Cancer Treatment Approved in The U.S.

The treatment landscape of metastatic prostate cancer - ScienceDirect

The Hospitalization-Related Costs of Adverse Events for Novel